Effect of square-stepping exercises on mobility, balance and knee joint position sense in individuals with multiple sclerosis
Related Experiment Video
Updated: Oct 31, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
Muge Icelli Gunes1, Tuba Can Akman2
1Denizli Vocational School of Health Services, Pamukkale University, Denizli, Turkey.
Background:
Multiple sclerosis (MS) is associated with impaired mobility, balance, and lower-limb position sense.
Objective:
This study aimed to investigate the effects of Square-Stepping Exercise (SSE), a task-oriented sensorimotor stepping intervention, on mobility, balance, and knee joint position sense (JPS) in people with MS.
Methods:
Forty individuals with MS, aged 20-50 years, were randomly allocated (1:1) to either the SSE group (n = 20) or the home-based Frenkel Coordination Exercise (FCE) group (control; n = 20). Both groups participated in their respective exercise programs twice weekly for eight weeks. Assessments were performed at baseline and post-intervention. Mobility and balance were assessed using the Timed 25-Foot Walk (T25FW), Five-Repetition Sit-to-Stand Test (5STS), Four Square Step Test (FSST), and the Activities-specific Balance Confidence Scale (ABC). Knee JPS was assessed using the K-FORCE Sens® device at target knee extension angles of 30° and 60°.
Results:
Baseline-adjusted analysis of covariance (ANCOVA) revealed significant between-group differences favoring SSE, with large effect sizes, for T25FW (p < .001; Hedges' g = -1.17), FSST (p < .001; g = -2.27), and ABC (p < .001; g = 1.23). Significant between-group differences favoring SSE were also observed for all knee JPS outcomes, with effect sizes ranging from small to large (p = .004-0.024; g = -0.45 to -0.80). No adjusted between-group difference was found for 5STS (p = .451; g = 0.22, small effect).
Conclusion:
The SSE intervention was associated with favorable changes in mobility, balance, and knee JPS outcomes in individuals with MS.
Trial Registration:
This trial was registered with ClinicalTrials.gov (NCT05682963) on December 24, 2022.
